Contributions
Abstract: PB1634
Type: Publication Only
Background
The prognosis of adult acute lymphoblastic leukemia (ALL) is dire, with a long-term survival of 40-50%. This disease entity is probably more frequent in the Latino population. Several studies have reported a worse prognosis in Hispanics with ALL as well as a greater incidence of the Ph-like genetic signature; however, the data is inconclusive in the Mexican population and there are no existing large multicenter series of ALL patients in Mexico that analyze survival.
Aims
The aim of this study was to describe the incidence, clinical and biologic characteristics as well as the survival of ALL patients in 5 referral hospitals in Mexico City.
Methods
A working group known as the Grupo de Trabajo de Leucemia Aguda (GTLA), was created as a result of an initiative of the Mexican Group for the Study of Hematology (Agrupación Mexicana para el Estudio de le Hematología) to promote acute leukemia research in Mexico. This is the first report of the GTLA which includes 5 referral hospitals in Mexico City. A retrospective, multicenter, descriptive study of adult ALL patients treated between 2009 and 2015 was conducted.
Results
We included 559 adults in 5 centers in Mexico City. Their median age was 28 years (14-81): adolescents and young adults (AYA) 67.3%; adults 24.7% and elderly adults 8.1%. Tumor lysis syndrome was detected in 9.8% of all cases.
Conclusion
Outcomes are poor in adult ALL patients treated in these referral centers in Mexico City. This may be explained by the high incidence of AYA patients and the low frequency with which they are treated with regimens containing L-asparaginase. The incidence of the Philadelphia chromosome is lower than reported, which could be due to a real difference between populations or due to aspects related to cytogenetic techniques. Based on these results, the GTLA´s objectives will be: to standardize diagnostic testing (immunophenotype and cytogenetics), improve early CR rates, standardize support care to decrease deaths during induction as well as treatment -related deaths, and increase the percentage of patients treated with AlloHPCT. Studies to determine the prevalence of the Ph-like genetic signature will be of great relevance in our population.
Session topic: 2. Acute lymphoblastic leukemia - Clinical
Keyword(s): Survival, adult, Acute lymphoblastic leukemia
Abstract: PB1634
Type: Publication Only
Background
The prognosis of adult acute lymphoblastic leukemia (ALL) is dire, with a long-term survival of 40-50%. This disease entity is probably more frequent in the Latino population. Several studies have reported a worse prognosis in Hispanics with ALL as well as a greater incidence of the Ph-like genetic signature; however, the data is inconclusive in the Mexican population and there are no existing large multicenter series of ALL patients in Mexico that analyze survival.
Aims
The aim of this study was to describe the incidence, clinical and biologic characteristics as well as the survival of ALL patients in 5 referral hospitals in Mexico City.
Methods
A working group known as the Grupo de Trabajo de Leucemia Aguda (GTLA), was created as a result of an initiative of the Mexican Group for the Study of Hematology (Agrupación Mexicana para el Estudio de le Hematología) to promote acute leukemia research in Mexico. This is the first report of the GTLA which includes 5 referral hospitals in Mexico City. A retrospective, multicenter, descriptive study of adult ALL patients treated between 2009 and 2015 was conducted.
Results
We included 559 adults in 5 centers in Mexico City. Their median age was 28 years (14-81): adolescents and young adults (AYA) 67.3%; adults 24.7% and elderly adults 8.1%. Tumor lysis syndrome was detected in 9.8% of all cases.
Conclusion
Outcomes are poor in adult ALL patients treated in these referral centers in Mexico City. This may be explained by the high incidence of AYA patients and the low frequency with which they are treated with regimens containing L-asparaginase. The incidence of the Philadelphia chromosome is lower than reported, which could be due to a real difference between populations or due to aspects related to cytogenetic techniques. Based on these results, the GTLA´s objectives will be: to standardize diagnostic testing (immunophenotype and cytogenetics), improve early CR rates, standardize support care to decrease deaths during induction as well as treatment -related deaths, and increase the percentage of patients treated with AlloHPCT. Studies to determine the prevalence of the Ph-like genetic signature will be of great relevance in our population.
Session topic: 2. Acute lymphoblastic leukemia - Clinical
Keyword(s): Survival, adult, Acute lymphoblastic leukemia